ClinicalTrials.gg
CompletedNCT02124746Updated Jun 18, 2023Results posted

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

A Phase 2 interventional study of Momelotinib in Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Sierra Oncology LLC - a GSK company. Completed at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing momelotinib in Primary Myelofibrosis — 3 open to participants now, 4 under way, none of them phase 3. momelotinib · Primary Myelofibrosis.

Enrollment
8th of 12
87 · median 138
Started
2014
with 1 other
Phase 2
5 of 12
1 open now
Registered
6th of 12
by date
Lead sponsor
8 of 12
Sierra Oncology LLC - a GSK company

Among the 12 studies testing momelotinib in Primary Myelofibrosis, this one is the 8th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 6th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 12 studies testing momelotinib in Primary Myelofibrosis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About momelotinib

momelotinib: first FDA approval 2023 (OJJAARA), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing momelotinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.

03

Conditions studied

  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Post-Essential Thrombocythemia Myelofibrosis
  • Polycythemia Vera
  • Essential Thrombocythemia

Keywords

  • Primary Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis
  • Post Essential Thrombocythemia Myelofibrosis
  • Polycythemia Vera
  • Essential Thrombocythemia
  • blood disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently enrolled in study CCL09101E, or YM387-II-02, or successfully completed 24 weeks of study GS-US-352-1672
  • Able to comprehend and willing to sign form

Key Exclusion Criteria:

  • Known to momelotinib, its metabolites, or formulation

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.

    Drug: Momelotinib

  • Experimental
    Cohort 2

    Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.

    Drug: Momelotinib

  • Experimental
    Cohort 3

    Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years. Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated.

    Drug: Momelotinib

  • Experimental
    Cohort 4

    Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.

    Drug: Momelotinib

Interventions

  • Momelotinib tablets administered orally once daily

    Also known as: GS-0387, CYT387

06

What researchers measure

Primary outcomes

  1. Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities

    Long-term safety and tolerability profile of momelotinib based on safety data (adverse events and selected hematology and chemistry laboratory parameters) collected after the first dose of momelotinib in the parent study.

    Time frame: From the first dose of momelotinib in the parent study to 30 days following permanent discontinuation of momelotinib in Study GS-US-352-1154.

Secondary outcomes

  1. Splenic Response Rate

    The number of subjects achieving a spleen response, defined as a reduction of 50% or more in palpable splenomegaly of a spleen that was at least 10 cm below the LCM at baseline, or a spleen that was palpable at \> 5 cm and \< 10 cm below the LCM at baseline becoming not palpable for at least 56 days, using baseline of the parent study as the reference.

    Time frame: From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.

  2. Duration of Splenic Response

    The interval from the first onset of splenic response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of splenic response. Loss of response was defined as the reduction of splenomegaly by \< 50% among responders (with splenomegaly ≥ 10 cm below the LCM at baseline) that lasts ≥ 56 days, or the recurrence of \> 0 cm splenomegaly among responders (with splenomegaly \> 5 and \< 10 cm at baseline) that lasts ≥ 56 days. Duration of splenic response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.

    Time frame: From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.

  3. Transfusion Independence Response Rate

    The number of transfusion dependent subjects at entry to a parent study who became transfusion-independent for ≥ 12 weeks at any time from the first dose of momelotinib in the parent study until the end of Study GS-US-352-1154.

    Time frame: From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.

  4. Duration of Transfusion Independence Response

    The interval from the first onset date of transfusion independence (in the parent study or Study GS-US-352-1154) to the earliest date of loss of response for participants who are transfusion dependent at baseline in the parent study. Loss of TI response was defined as receiving an RBC transfusion after achieving a TI response. Duration of transfusion independence response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.

    Time frame: From baseline in the parent study until the last assessment date in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.

  5. Anemia Response Rate

    The number of subjects achieving an anemia response, defined as: * Achieving transfusion independence for ≥ 12 weeks, for subjects who were transfusion-dependent at baseline in the parent study, or * Having ≥ 2 g/dL increase in Hgb from baseline for ≥ 12 weeks, for subjects with Hgb \< 10 g/dL at baseline in the parent study who were not transfusion-dependent (Cohort 1) or who were transfusion-independent (Cohort 2).

    Time frame: From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.

  6. Duration of Anemia Response

    The interval from the first onset of anemia response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of anemia response. Loss of anemia response was defined as having any RBC transfusion after achieving an anemia response. Duration of anemia response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.

    Time frame: From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.

  7. Rate of RBC Transfusion

    The average number of RBC units per subject month during the parent study and/or Study GS-US-352-1154.

    Time frame: From the first dose of momelotinib in the parent study until the last dose of momelotinib in Study GS-US-352-1154.

  8. Overall Survival

    The interval from the first dose of momelotinib in the parent study until death from any cause. Overall survival was analyzed using the Kaplan-Meier method. Data from subjects who were lost to follow-up or remained alive until the end of the study were censored at the date of last contact or last response assessment.

    Time frame: From baseline in the parent study until the date of last contact or last response assessment, up to 30 days following permanent discontinuation of momelotinib.

  9. Progression-Free Survival

    The interval from the first dose of momelotinib in the parent study until the first documentation of definitive progressive disease as defined in 2006 IWG-MRT or death due to any cause. Subjects who were free of progression were censored at the last assessment date.

    Time frame: From baseline in the parent study until the last response assessment, up to 30 days following permanent discontinuation of momelotinib.

  10. Leukemia-Free Survival

    The interval from the first dose of momelotinib in the parent study until the first documented leukemic transformation or death from any cause. Leukemic transformation was documented in the adverse event electronic case report form. Leukemia-free survival was analyzed using the Kaplan-Meier method. Subjects who were free of leukemia transformation were censored at the last assessment date.

    Time frame: From baseline in the parent study until the date of the last assessment, up to 30 days following permanent discontinuation of momelotinib.

07

Results

Posted Feb 5, 2021
Limitations and caveats
Cohort 3 was discontinued and excluded from the safety and efficacy analyses. The survival analyses were subject to a high level of censoring.

Participant flow

Benefiting subjects enrolled in 1 of 3 prior momelotinib (MMB) studies (parent studies) for the treatment of MF were included for continued dosing of MMB. Cohort 3 (PV/ET; n=13) was closed and subjects were discontinued due to limited efficacy of MMB in the treatment of PV/ET observed in the parent study. Cohort 3 was excluded from all analyses.

Participant flow — Overall Study
MilestoneCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)
Started302222
Completed1140
Not completed191822
Withdrew: Adverse event212
Withdrew: Death213
Withdrew: Lack of efficacy322
Withdrew: Physician decision645
Withdrew: Non-compliance with study drug010
Withdrew: Withdrawal by subject330
Withdrew: Study terminated by sponsor006
Withdrew: Disease progression364

Outcome measures

PrimaryLong Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities

Long-term safety and tolerability profile of momelotinib based on safety data (adverse events and selected hematology and chemistry laboratory parameters) collected after the first dose of momelotinib in the parent study.

Time frame:
From the first dose of momelotinib in the parent study to 30 days following permanent discontinuation of momelotinib in Study GS-US-352-1154.
Reported as:
Count of participants · Participants
Long Term Safety and Tolerability as Measured by the Incidence and Severity of Adverse Events and Clinical Laboratory Abnormalities
ParticipantsTotal
Subjects with ≥ one AE (any grade)73
Subjects with ≥ one Grade 3 or higher AE62
Subjects with Grade 3 lab toxicity (highest grade)36
Subjects with Grade 4 lab toxicity (highest grade)16
SecondarySplenic Response Rate

The number of subjects achieving a spleen response, defined as a reduction of 50% or more in palpable splenomegaly of a spleen that was at least 10 cm below the LCM at baseline, or a spleen that was palpable at \> 5 cm and \< 10 cm below the LCM at baseline becoming not palpable for at least 56 days, using baseline of the parent study as the reference.

Time frame:
From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Count of participants · Participants
Splenic Response Rate
ParticipantsCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Splenic Response Rate2019645
SecondaryDuration of Splenic Response

The interval from the first onset of splenic response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of splenic response. Loss of response was defined as the reduction of splenomegaly by \< 50% among responders (with splenomegaly ≥ 10 cm below the LCM at baseline) that lasts ≥ 56 days, or the recurrence of \> 0 cm splenomegaly among responders (with splenomegaly \> 5 and \< 10 cm at baseline) that lasts ≥ 56 days. Duration of splenic response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.

Time frame:
From baseline in the parent study until the last spleen assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Median · days
Duration of Splenic Response
daysCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Duration of Splenic Response1704.5 (1153.5 to 2682.0)736.0 (197.0 to 1070.0)447.5 (128.0 to 758.0)990.0 (226.0 to 1802.0)
SecondaryTransfusion Independence Response Rate

The number of transfusion dependent subjects at entry to a parent study who became transfusion-independent for ≥ 12 weeks at any time from the first dose of momelotinib in the parent study until the end of Study GS-US-352-1154.

Time frame:
From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Count of participants · Participants
Transfusion Independence Response Rate
ParticipantsCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Transfusion Independence Response Rate751628
SecondaryDuration of Transfusion Independence Response

The interval from the first onset date of transfusion independence (in the parent study or Study GS-US-352-1154) to the earliest date of loss of response for participants who are transfusion dependent at baseline in the parent study. Loss of TI response was defined as receiving an RBC transfusion after achieving a TI response. Duration of transfusion independence response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.

Time frame:
From baseline in the parent study until the last assessment date in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Median · days
Duration of Transfusion Independence Response
daysCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Duration of Transfusion Independence Response357.0 (117.0 to 1841.0)114.0 (95.0 to 126.0)281.5 (110.0 to 633.5)193.5 (110.0 to 701.0)
SecondaryAnemia Response Rate

The number of subjects achieving an anemia response, defined as: * Achieving transfusion independence for ≥ 12 weeks, for subjects who were transfusion-dependent at baseline in the parent study, or * Having ≥ 2 g/dL increase in Hgb from baseline for ≥ 12 weeks, for subjects with Hgb \< 10 g/dL at baseline in the parent study who were not transfusion-dependent (Cohort 1) or who were transfusion-independent (Cohort 2).

Time frame:
From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Count of participants · Participants
Anemia Response Rate
ParticipantsCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Anemia Response Rate1361635
SecondaryDuration of Anemia Response

The interval from the first onset of anemia response (in the parent study or Study GS-US-352-1154) to the earliest date of loss of anemia response. Loss of anemia response was defined as having any RBC transfusion after achieving an anemia response. Duration of anemia response was measured by descriptive statistics. Data from responders who maintained their response was censored at the last assessment date.

Time frame:
From baseline in the parent study until the last assessment in Study GS-US-352-1154, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Median · days
Duration of Anemia Response
daysCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Duration of Anemia Response995.0 (297.0 to 1841.0)120.0 (95.0 to 744.0)281.5 (110.0 to 633.5)358.0 (114.0 to 954.0)
SecondaryRate of RBC Transfusion

The average number of RBC units per subject month during the parent study and/or Study GS-US-352-1154.

Time frame:
From the first dose of momelotinib in the parent study until the last dose of momelotinib in Study GS-US-352-1154.
Reported as:
Median · RBC units per month
Rate of RBC Transfusion
RBC units per monthTotal
RBC Transfusion Rate in Parent Studies0.08 (0.0 to 5.4)
RBC Transfusion Rate in Study GS-US-352-11540.00 (0.0 to 4.8)
RBC Transfusion Rate Since 1st Dose in ParentStudy0.06 (0.0 to 4.9)
SecondaryOverall Survival

The interval from the first dose of momelotinib in the parent study until death from any cause. Overall survival was analyzed using the Kaplan-Meier method. Data from subjects who were lost to follow-up or remained alive until the end of the study were censored at the date of last contact or last response assessment.

Time frame:
From baseline in the parent study until the date of last contact or last response assessment, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Median · months
Overall Survival
monthsCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Overall SurvivalNA (36.7 to 99.6)NA (28.1 to 81.6)NA (6.3 to 29.6)NA (6.3 to 99.6)
SecondaryProgression-Free Survival

The interval from the first dose of momelotinib in the parent study until the first documentation of definitive progressive disease as defined in 2006 IWG-MRT or death due to any cause. Subjects who were free of progression were censored at the last assessment date.

Time frame:
From baseline in the parent study until the last response assessment, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Median · months
Progression-Free Survival
monthsCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Progression-Free SurvivalNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryLeukemia-Free Survival

The interval from the first dose of momelotinib in the parent study until the first documented leukemic transformation or death from any cause. Leukemic transformation was documented in the adverse event electronic case report form. Leukemia-free survival was analyzed using the Kaplan-Meier method. Subjects who were free of leukemia transformation were censored at the last assessment date.

Time frame:
From baseline in the parent study until the date of the last assessment, up to 30 days following permanent discontinuation of momelotinib.
Reported as:
Median · months
Leukemia-Free Survival
monthsCohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Leukemia-Free SurvivalNA (36.7 to 99.6)NA (28.1 to 81.6)NA (6.1 to 29.6)NA (6.1 to 99.6)

Adverse events

Collected over From the first dose of momelotinib in the parent study until 30 days after the last dose in Study GS-US-352-1154.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total8/74 (10.8%)49/74 (66.2%)73/74 (98.6%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventTotal
PneumoniaInfections and infestations7/74
Abdominal painGastrointestinal disorders6/74
Acute kidney injuryRenal and urinary disorders5/74
Cardiac failure congestiveCardiac disorders4/74
Lung infectionInfections and infestations4/74
SepsisInfections and infestations3/74
Urinary tract infectionInfections and infestations3/74
DyspnoeaRespiratory, thoracic and mediastinal disorders3/74
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/74
Febrile neutropeniaBlood and lymphatic system disorders2/74
Most frequent other events
Showing 10 of 109
Most frequent other events
EventTotal
DiarrhoeaGastrointestinal disorders41/74
FatigueGeneral disorders35/74
NauseaGastrointestinal disorders33/74
Peripheral sensory neuropathyNervous system disorders31/74
DyspnoeaRespiratory, thoracic and mediastinal disorders29/74
ThrombocytopeniaBlood and lymphatic system disorders28/74
DizzinessNervous system disorders28/74
HeadacheNervous system disorders28/74
AnaemiaBlood and lymphatic system disorders27/74
Abdominal painGastrointestinal disorders23/74

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Median66.0 (34.0 to 82.0)64.0 (48.0 to 80.0)68.0 (44.0 to 88.0)66.5 (34.0 to 88.0)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Female1710936
Male13121338
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
White26201864
Black or African American0224
Asian2002
Hispanic or Latino1001
Other1023
Transfusion Dependent (at baseline in parent study)
Transfusion Dependent (at baseline in parent study)(Participants)Cohort 1 (CCL09101/ CCL09101E/ GS-US-352-1154)Cohort 2 (YM387-II-02/GS-US-352-1154)Cohort 4 (GS-US-352-1672/GS-US-352-1154)Total
Yes772236
No2312035
Missing0303
08

Study locations

22 sites
  • Scottsdale, Arizona, United States
  • Orange, California, United States
  • Stanford, California, United States
  • Whittier, California, United States
  • Jacksonville, Florida, United States
  • Baltimore, Maryland, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Rochester, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Bronx, New York, United States
  • New York, New York, United States
  • Cleveland, Ohio, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Frankston, Victoria, Australia
  • Parkville, Victoria, Australia
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
  • La Tronche, France
  • Paris, France
  • Minden, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Dec 2018, 55 months.

Results were first posted in Feb 2021, 2 years 1 month after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 55 months is above that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2014
First posted
Apr 28, 2014
StartActual
Apr 30, 2014
Primary completionActual
Dec 6, 2018
CompletionActual
Dec 6, 2018
Results first posted
Feb 5, 2021
Last update
Jun 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02124746
Responsible party
Sponsor
First posted
Apr 28, 2014
Start date
Apr 30, 2014
Primary completion
Dec 6, 2018
Completion
Dec 6, 2018
Results posted
Feb 5, 2021
Last update
Jun 18, 2023

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Momelotinib

Start the discussion